IE58927B1 - Contraceptive method and kit - Google Patents

Description

The study of the prevention of pregnancy in human females has led to the evolution of «any hornone-’based compositions. Some compositions contain both estrogenic' and progestogenie compounds. Such compositions, referred to herein as estrogen/progestogen combinations, are highly effective in controlling ovulation and conception.

Hany estrogen/progestogen combination formulations suffer from the drawback that they induce, in a significant number of females, unwanted side effects,, such as breakthrough bleeding or spotting. Applicant has discovered that such side effects can be minimised via the concomitant us® of (1) particular estrogen/ progestogen combinations and (2) administration of those combinations at appropriately-timed intervals,, It has been discovered that the unwanted side effects generally associated with the administration of estrogen/progesterone contraceptive schemes can be minimised when the compositions used correspond to phases containing, in sequence, 0.,5-1..5 mg norethindrone acetate and -50 meg ethinyl estradiol for the first phase (Phase I) mg norethindrone acetate and -50 meg ethinyl estradiol in the second phase (Phase ID; 0.5-1.5 0.5-1.5 mg norethindrone acetate and 10-50 meg ethinyl estradiol in the third phase (Phase III) and a suitable quantity of an iron supplement, e.g., ferrous fumarate, or other non-steroidal agent or placebo in an optional fourth, or inactive, phase (Phase IV). It is essential that the phases succeed each other in increasing numeric order (i.e., ϊ, II, III, IV).

Applicant's combinations can b® characterised in that the amount of estrogen employed in any two phases i© never the same. That is, th® amount of ethinyl β) estradiol or other estrogenic component is different for each composition with different compositions being used in each phase.

U.S. Patent 4,390,531 uses norethindrone as the progestogenic component in one type of estrogen/protestogen combination. However, such combinations ar© generally associated with high incidence of breakthrough bleeding» Furthermore, Applicant employs a highly active progestogenic compound, eliminating the need for large amounts of this component» Applicant's four-phase system can be administered in 23- to 34-day cycles, with 21- to 28-day cycles preferred. Generally, the first phase will be 4 to 7 days? the second will be 5 co 8 days? the third will be 7 to 12 days? and the fourth, or last, will be 7 days.

The invention has several advantages over prior art methods which employ estrogen/progestogen combinations. Principal among its advantages are ease of administration and similarity to the natural menstrual cycle -- i.e., similarity to cycles experienced by females who do not use contraceptive drugs.

In addition, use of the invention will potentially produce fewer side effects, most particularly, breakthrough bleeding. The compositions used herein preferably contain norethindrone acetate, a progestogenic component having less potency - and, concomitantly, producing lower incidence of breakthrough bleeding than other progestogenic agents, e.g», norethindrone.

Other advantages and aspects of the invention will be apparent from a consideration of the following description.

The invention covers a method and kit for the use of a multiphase, sequentially-administered combination of compositions.

In one aspect, the invention deals with a method of contraception comp rising the steps of sequentially administering, to a female of child bearing ages (1) for 4 to 7 days, a composition 1 containing norethindrone acetate and ethinyl estradiol, (2) for 5 to 8 days, a composition II containing norethindrone acetate and ethinyl estradiol, and (3) for 7 to 12 days, a composition III containing norethindrone acetate and ethinyl estradiol; wherein compositions I, II and III each contain from 0.5 to 1.5 mg norethindrone acetate and 10 to 50 pg ethinyl estradiol, and wherein the amount of ethinyl estradiol is increased stepwise over the three compositions I, II and III.

In another aspect, the invention is concerned with a multiphase combination and contraceptive kit comprising a package containing daily dosages of: (1) a Phase I composition containing norethindrone acetate and ethinyl estradiol; (2) a Phase II composition containing norethindrone acetate and ethinyl estradiol; and (3) a Phase III composition containing norethindrone acetate and ethinyl estradiol.

An optional Phase IV composition, which contains an iron supplement, e.g., ferrous fumarate, and/or one or more placebos, can be used in conjunction with the other three..

The compositions are consumed or administered in a numeric sequence with the Phase X composition being used first, the Phase II composition being used second, etc. If packaging and/or other requirements dictate, the method and kit described herein can be employed as part of a larger scheme for contraception or treatment of gynecological disorders. While the sequence in which Applicant's combinations ar® administered is important to their operation, it should be kept in mind that variations in timing and dosage can be tolerated when medical considerations so dictate.

The compositions employed in accordance with the invention in Phases Ϊ through XV will preferably have e the administration times and drug contents set forth in the following cable when a four-phase system is used. The table sets forth relevant values for one of our preferred embodiments, or configurations, for administration of th® system to females,, Table Phase Administration Interval, Davs Norethindrcne Acetate, ma Ethinyl Estradiol meg Ferrous s Elmarate, X 5 1,0 20 0 II 7 i.S 3-0 0 III 9 1.0 50 © IV 7 0 0 75 15 The noretftindrone acetate used in th® table is ίπτ Norlutate , a product manufactured by the Parke-Davis Division of Warner-Lambert Companys Morris Plains, Mew Jersey., The designation 'meg® refers to micrograms and 20 “^9” to milligrams.

It should be noted that this table is presented for illustrative purposes only. The substitution of functionally equivalent amounts and kinds of reagent(s) in these schemes is contemplated. For * Trade Mark • xawple, the use of sugar or other placebo in place of «11 or part of the ferrous fumarate is envisioned.

In addition, th© use of other conventional additives, e.g., fillers, colorants and polymeric binders is also contemplated. In general any pharmaceutically-acceptable additive which does not interfere with the function of the active components can be used in on© or more of the compositions.

Suitable carriers with which the compositions can be administered include lactose, starch and cellulose derivatives used in suitable amounts.

Lactose is a preferred carrier. Mixtures of carriers are operable.

/, While the invention is discussed as one employing four phases, it may employ only three. Phase IV is not essential to the operation of th© other three distinct phases. Thus a method or kit which does not contain the Phase IV component is operable and, in fact, will be preferred when suitable factors, e.g,, economy, dictate the non-use of the Phase iv component.

The terms method*1 and kit are used herein to encompass any drug delivery systems via the us© of which the 3- or 4- phase scheme outlined above can be effectively administered to human females. Combinations of various dosage forms are operable.

As this description illustrates, applicant has discovered that a unique dosage pattern, i.e., a unique sequence of administrations of a novel estrogen/ progestogen combination minimize certain side effects, notably breakthrough bleeding, commonly associated with conventional low dosage pills.

The administration sequence, i.e-, the administration of the first pill or other dosage form containing the first dosage of composition 1 e should take place from about 5 to about 7 days after the start of menstruation (counting the first day of menstruation as day 1),,, preferably on or about the fifth day after the onset of menstruation. However, for ease of administration and to facilitate patient compliance^ it is desirable to administer the first dosage of the first composition on or about the first Sunday after the menstrual pex-iod starts.

The use of the word about in relation to a range of days snav mean that specific figures mentioned can be increased or decreased by up to twelve hours (e.g. 1f 2, 3 υ 5P 6, 7 p 8P 9, 1 0 e, 11 or 12 hours).,

Claims (12)

1. CL&ms

1. A method of contraception comprising the steps os sequentially-administering to a female of child bearing ages (1) for 4 to 7 days, a composition I containing norethindrone acetate and ethinyl estradiol,, (2> for 5 to 8 days, a composition II containing norethindrone acetate and ethinyl estradiol, and (3) for 7 to 12 days, a composition III containing norethindrone acetate and ethinyl estradiolj wherein compositions I, II and III each contain from 0.5 to 1.5 mg norethindrone acetate and 10 to 50 ug ethinyl estradiol, and wherein the amount of ethinyl estradiol is increased stepwise over the three compositions I, II and III.

2. The method of claim 1 which comprises the additional step of administering, for 7 days, a composition IV containing ferrous fumarate.

3. The method of - claim! 1 or 2, wherein composition I is administered for about 5 days and contains about 1.0 mg norethindrone acetate .and about 20 ' pg ethinyl estradiol:? composition II is administered for about 7 days and contains about 1.5 mg norethindrone acetate and about 30 pg ethinyl estradiolj and composition III is administered for about 9 days and contains about 1.0 mg norethindrone acetate and about 50 p.g ethinyl estradiol.

4. The method of any preceding claim, wherein at least one composition is administered in combination with a suitable carrier.

5. A multiphase combination and contraceptive kit comprising a package containing daily dosages ofs (1) a Phase I composition containing norethindrone acetate and ethinyl estradiol? 2. (2) a Phase II composition containing norethindrone acetate and ethinyl estradiol? and (3) a Phase III composition containing norethindrone acetate and ethinyl estradiol wherein the compositions for Phases I f II and III each contain in the range of from 0.5 to 1.5 mg 5 norethindrone acetate, and from 10 to 50 pg ethinyl estradiol, and wherein the amount of ethinyl estradiol is increased stepwise over the three compsoitions I, II and III.

6. The kit of claim 5 which additionally 10 comprises a Phase IV composition containing ferrous fumarate.

7. The kit of claim 6, wherein the composition for Phase IV contains about 75 mg ferrous fum&rate.

8. The kit according to any of claims 5 to 7, 15 containing about 5 dosages of the Phase I composition, about 6 dosages of the Phase II composition, and about 10 dosages of the Phase III composition.

$. The kit according to any of claims 5 to 7, wherein the Phase I composition contains about 1-0 mg 20 norethindrone acetate and about 20 ug ethinyl estradiol; the Phase II composition contains about 1.5 mg norethindrone acetate and about 30 pg ethinyl estradiol; and the Phase III composition contains about 1.0 mg norethindrone acetate and about 50 pg ethinyl 25 estradiol.

10. The kit of claim 9, containing about 5 dosages of the Phase I composition, about 7 dosages of the Phase II composition, and about 9 dosages of the Phase III composition. 30

11. The kit of claim 10 when appendant to claim δ which additionally contains about 7 dosages of the Phase IV composition»

12. The kit of claim 8 when appendant to claim S which additionally contains about 7 dosages of the 35 Phase IV composition.